Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection

Harmony L. Tyner, Jefferey L Burgess, Lauren Grant, Manjusha Gaglani, Jennifer L. Kuntz, Allison L. Naleway, Natalie J. Thornburg, Alberto J. Caban-Martinez, Sarang K. Yoon, Meghan K. Herring, Shawn C. Beitel, Lenee Blanton, Janko Nikolich-Zugich, Matthew S. Thiese, Jessica Flores Pleasants, Ashley L. Fowlkes, Karen Lutrick, Kayan Dunnigan, Young M.Yoo, Spencer Rose, Holly Groom, Jennifer Meece, Meredith G. Wesley, Natasha Schaefer-Solle, Paola Louzado-Feliciano, Laura J. Edwards, Lauren E. W. Olsho, Mark G. Thompson
doi: https://doi.org/10.1101/2021.10.20.21265171
Harmony L. Tyner
1St. Luke’s Regional Health Care System, Duluth, Minnesota, USA
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jefferey L Burgess
2the Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona, Tucson, Arizona, USA
M.D., M.S., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Grant
3the Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manjusha Gaglani
4Baylor Scott and White Health, Temple, Texas, USA
5Texas A&M University College of Medicine, Temple, Texas, USA
M.B.B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L. Kuntz
6Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison L. Naleway
6Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie J. Thornburg
3the Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto J. Caban-Martinez
7the Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA
D.O., Ph.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarang K. Yoon
8Department of Family and Preventive Medicine, University of Utah Health, Salt Lake City, Utah, USA
D.O., M.O.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meghan K. Herring
9Abt Associates, Inc, Rockville, Maryland, USA
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn C. Beitel
2the Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona, Tucson, Arizona, USA
M.Sc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lenee Blanton
3the Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janko Nikolich-Zugich
2the Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona, Tucson, Arizona, USA
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew S. Thiese
8Department of Family and Preventive Medicine, University of Utah Health, Salt Lake City, Utah, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Flores Pleasants
9Abt Associates, Inc, Rockville, Maryland, USA
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley L. Fowlkes
3the Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
Sc.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Lutrick
2the Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona, Tucson, Arizona, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayan Dunnigan
4Baylor Scott and White Health, Temple, Texas, USA
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young M.Yoo
3the Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
M.S.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spencer Rose
4Baylor Scott and White Health, Temple, Texas, USA
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Groom
6Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Meece
10the Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meredith G. Wesley
9Abt Associates, Inc, Rockville, Maryland, USA
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha Schaefer-Solle
7the Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA
Ph.D., R.N.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Louzado-Feliciano
7the Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura J. Edwards
9Abt Associates, Inc, Rockville, Maryland, USA
M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren E. W. Olsho
9Abt Associates, Inc, Rockville, Maryland, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark G. Thompson
3the Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: isq8{at}cdc.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Data on the development of neutralizing antibodies against SARS-CoV-2 after SARS-CoV-2 infection and after vaccination with messenger RNA (mRNA) COVID-19 vaccines are limited.

Methods From a prospective cohort of 3,975 adult essential and frontline workers tested weekly from August, 2020 to March, 2021 for SARS-CoV-2 infection by Reverse Transcription- Polymerase Chain Reaction (RT-PCR) assay irrespective of symptoms, 497 participants had sera drawn after infection (170), vaccination (327), and after both infection and vaccination (50 from the infection population). Serum was collected after infection and each vaccine dose. Serum- neutralizing antibody titers against USA-WA1/2020-spike pseudotype virus were determined by the 50% inhibitory dilution. Geometric mean titers (GMTs) and corresponding fold increases were calculated using t-tests and linear mixed effects models.

Results Among 170 unvaccinated participants with SARS-CoV-2 infection, 158 (93%) developed neutralizing antibodies (nAb) with a GMT of 1,003 (95% CI=766-1,315). Among 139 previously uninfected participants, 138 (99%) developed nAb after mRNA vaccine dose-2 with a GMT of 3,257 (95% CI = 2,596-4,052). GMT was higher among those receiving mRNA-1273 vaccine (GMT =4,698, 95%CI= 3,186-6,926) compared to BNT162b2 vaccine (GMT=2,309, 95%CI=1,825-2,919). Among 32 participants with prior SARS-CoV-2 infection, GMT was 21,655 (95%CI=14,766-31,756) after mRNA vaccine dose-1, without further increase after dose- 2.

Conclusions A single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed nAb response. Two doses of mRNA vaccine in previously uninfected participants resulted in higher nAb to SARS-CoV-2 than after one dose of vaccine or SARS- CoV-2 infection alone. Neutralizing antibody response also differed by mRNA vaccine product.

Main Point Summary One dose of mRNA COVID-19 vaccine after previous SARS-CoV-2 infection produced the highest neutralizing antibody titers; among those without history of infection, two doses of mRNA vaccine produced the most robust response.

Competing Interest Statement

Allison Naleway receives research funding from Pfizer and Vir Biotechnology and Jennifer Kuntz receives research funding from Pfizer, Novartis, and Vir Biotechnology for unrelated studies. All other authors: No conflicts.

Funding Statement

This work was supported by the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases [contracts 75D30120R68013 to Marshfield Clinic Research Institute, 75D30120C08379 to the University of Arizona, and 75D30120C08150 to Abt Associates].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study is governed by Centers for Disease Control and Prevention IRB review board and gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • CDC Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted October 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
Harmony L. Tyner, Jefferey L Burgess, Lauren Grant, Manjusha Gaglani, Jennifer L. Kuntz, Allison L. Naleway, Natalie J. Thornburg, Alberto J. Caban-Martinez, Sarang K. Yoon, Meghan K. Herring, Shawn C. Beitel, Lenee Blanton, Janko Nikolich-Zugich, Matthew S. Thiese, Jessica Flores Pleasants, Ashley L. Fowlkes, Karen Lutrick, Kayan Dunnigan, Young M.Yoo, Spencer Rose, Holly Groom, Jennifer Meece, Meredith G. Wesley, Natasha Schaefer-Solle, Paola Louzado-Feliciano, Laura J. Edwards, Lauren E. W. Olsho, Mark G. Thompson
medRxiv 2021.10.20.21265171; doi: https://doi.org/10.1101/2021.10.20.21265171
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
Harmony L. Tyner, Jefferey L Burgess, Lauren Grant, Manjusha Gaglani, Jennifer L. Kuntz, Allison L. Naleway, Natalie J. Thornburg, Alberto J. Caban-Martinez, Sarang K. Yoon, Meghan K. Herring, Shawn C. Beitel, Lenee Blanton, Janko Nikolich-Zugich, Matthew S. Thiese, Jessica Flores Pleasants, Ashley L. Fowlkes, Karen Lutrick, Kayan Dunnigan, Young M.Yoo, Spencer Rose, Holly Groom, Jennifer Meece, Meredith G. Wesley, Natasha Schaefer-Solle, Paola Louzado-Feliciano, Laura J. Edwards, Lauren E. W. Olsho, Mark G. Thompson
medRxiv 2021.10.20.21265171; doi: https://doi.org/10.1101/2021.10.20.21265171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3292)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13374)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14627)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)